Portage Biotech is a clinical stage immune-oncology company focused on overcoming immune resistance. Co. sources, nurtures and develops therapies for a variety of cancers, by funding, implementing product development strategies, clinical counsel/trial design, shared services, financial and project management to enable execution of commercially informed development plans. Co.'s drug development pipeline portfolio encompasses products or technologies based on biology addressing known resistance pathways/mechanisms of check point inhibitors with scientific rationales, including intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like particles. The PRTG average annual return since 2021 is shown above.
The Average Annual Return on the PRTG average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRTG average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRTG average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|